Management of postmenopausal osteoporosis (PMO) often presents complex decisions when treating women at high fracture risk, with rapid bone loss or contraindications to standard therapies. While bisphosphonates and denosumab remain foundational, their limitations especially in women with recent fractures or very low bone mineral density (BMD) highl
119 Reached
Complicated case of Osteoarthritis
1849 Reached2 Comments3 Likes
Pregnant Woman with HIV-1 Infection
747 Reached1 Likes
Use of Clindamycin for Managing Bacterial Vaginosis
11170 Reached29 Comments8 Likes
Switching from Premixed Insulin to Basal Insulin with OADs
1083 Reached2 Comments6 Likes
Case of Increased Risk of Pregnancy-associated Breast Cancer Recurrence
1007 Reached2 Comments